Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential - Poll - MDSpire

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

  • By

  • Michael Colwill

  • Sebastian Povlsen

  • Richard Pollok

  • Kamal Patel

  • James Goodhand

  • Tariq Ahmad

  • Sailish Honap

  • September 16, 2025

  • 0 min

Share

Original Source(s)

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

  • by Michael Colwill, Sebastian Povlsen, Richard Pollok, Kamal Patel, James Goodhand, Tariq Ahmad, Sailish Honap

  • September 16, 2025

Related Content

The role of the complement system in gastrointestinal-related diseases

Frontline Pharma: Sarah O’Keeffe

Ahead of HPLC 2026, Eli Lilly’s Sarah O’Keeffe reflects on leadership, collaboration, and the analytical advances helping bring increasingly complex medicines to patients

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation